We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Brain Signal Determines Stroke Outcome

By Biotechdaily staff writers
Posted on 30 Nov 2005
specific signal in brain cells may determine whether stroke patients live or die, suggesting that new therapies for stroke victims could be developed by controlling the signaling pathway, according to a new study published in the November 13, 2005, online issue of Nature Medicine.

Scientists at the University of Heidelberg (Germany) discovered that damaged and dying brain cells are using an internal "communications network” known as the NF-kB signaling pathway. More...
Evidence in nerve cells had suggested this pathway could trigger apoptosis. To clarify the function of the pathway, the scientists developed a "conditional knockout” mouse with a stroke-like condition in which a protein called IKK2 activated the pathway. This allowed them to shut down the NF-kB molecule at any time in neurons. Meanwhile, another group of investigators at the University of Ulm (Germany), working in parallel, had generated two additional mouse models that allowed the reversible repression or activation of IKK2 at any time in neurons.

By combining their findings, the researchers were able to obtain a clear picture of IKKs's role after a stroke. Mice with the hyperactive form of IKK2 in neurons and too much NF-kB signaling suffer more damage than normal and far more cells die. However, if the IKK2 signal is blocked, damaged cells stay alive and appear to recover even when the blocking is done a few hours after the stroke. Moreover, the effects are long-term: neurons in the damaged tissues were still alive several days after the stroke.

"The unique advantage of this system is that we can specifically induce or block this signaling pathway at virtually any time and selectively in neurons,” said Thomas Wirth, University of Ulm. He noted that the same effects could be achieved by blocking the IKK2 pathway with a small artificial molecule, which is what a drug would have to do.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.